CHELSEA PETTIT: Open Payments
NPI 1851973101 · DEARBORN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$865 in 20 payments from 7 companies in 2025. Trend: 2023 $545 · 2024 $61 · 2025 $865
Food & beverage: $865
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 2 | $249 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $197 |
| Ardelyx, Inc. | 4 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $103 |
| QOL Medical, LLC | 2 | $50 |
| ABBVIE INC. | 2 | $46 |
| Janssen Biotech, Inc. | 1 | $32 |
Products named: ZENPEP, XIFAXAN, IBSRELA, ENTYVIO, Sucraid, TREMFYA, SKYRIZI, LINZESS.
Industry payments across MI — which companies pay providers there.
